Nama's AI scorecard currently rates Axsome Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does AXSM report earnings?

Axsome Therapeutics's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.08.

What is the AXSM price target?

The median analyst price target from 21 analysts is $268.00, with a range of $220.00 – $380.00.

Is AXSM Shariah compliant?

Nama's AAOIFI-style screen reads Axsome Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Axsome Therapeutics (AXSM)

Healthcare · Biotechnology · NASDAQ

Axsome Therapeutics (AXSM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.96B and a free-cash-flow yield of -1.4%. Over the most recent reported fiscal year, revenue grew 65.5%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +24.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-49.1%

How far the last close sits under the highest price of the past five years.

Market cap	$6.96B
Trailing P/E	—
Price / book	83.2
Price / sales	8.9
FCF yield	-1.4%
Dividend yield	—
Gross margin	93.2%
Operating margin	-23.6%
Net margin	-24.7%
Revenue growth (YoY)	+65.5%
Revenue growth (3-yr annual)	+133.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

AXSM earnings

Next report: Feb 22, 2027 (Q4 2026, EPS estimate -$0.08). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	-$0.25	-$0.64	+60.9%	$259.69M
Q2 2026	Aug 10, 2026	-$0.99	-$0.78	-26.9%	$218.38M
Q1 2026	May 4, 2026	-$1.26	-$0.86	-46.5%	$191.20M
Q4 2025	Feb 23, 2026	-$0.56	-$0.73	+23.3%	$196.00M

AXSM analyst price target

Median target $268.00 from 21 analysts, ranging $220.00 – $380.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live AXSM data on Nama Insights →

AXSM FAQ

Is AXSM a buy?: Nama's AI scorecard currently rates Axsome Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does AXSM report earnings?: Axsome Therapeutics's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.08.
What is the AXSM price target?: The median analyst price target from 21 analysts is $268.00, with a range of $220.00 – $380.00.
Is AXSM Shariah compliant?: Nama's AAOIFI-style screen reads Axsome Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.